A drug used to counteract low white blood cell counts in individuals with breast cancer may also be inducing bone metastases (pages 26–27).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis
Scientific Reports Open Access 29 August 2017
-
Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292
Clinical & Experimental Metastasis Open Access 18 June 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chang, D.Z., Lomazow W., Joy Somberg, C., Stan, R. & Perales, M.A. Hematology 9, 207–215 (2004).
Park, B.K. et al. Nature Med. 13, 60–67 (2006).
Coleman, R.E. Cancer Treat. Rev. 27, 165–176 (2001).
Roodman, G.D. N. Engl. J. Med. 350, 1655–1664 (2004).
Mundy, G.R. Nat. Rev. Cancer 2, 584–593 (2002).
Kozlow, W. & Guise, T.A.J. Mammary Gland Biol. Neoplasia 10, 169–180 (2005).
Udagawa, N. et al. J. Exp. Med. 185, 1005–1012 (1997).
MacDonald, B.R. et al. J. Bone Miner. Res. 1, 227–233 (1986).
Menaa, C. et al. J. Clin. Invest. 103, 1605–1613 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roodman, G. Bone-breaking cancer treatment. Nat Med 13, 25–26 (2007). https://doi.org/10.1038/nm0107-25
Issue Date:
DOI: https://doi.org/10.1038/nm0107-25
This article is cited by
-
Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis
Scientific Reports (2017)
-
The best of both worlds — managing the cancer, saving the bone
Nature Reviews Endocrinology (2016)
-
Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma
Leukemia (2012)
-
Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292
Clinical & Experimental Metastasis (2011)